A high‐affinity, bivalent PDZ domain inhibitor complexes PICK1 to alleviate neuropathic pain

A high‐affinity, bivalent PDZ domain inhibitor complexes PICK1 to alleviate neuropathic pain

Abstract Maladaptive plasticity involving increased expression of AMPA‐type glutamate receptors is involved in several pathologies, including neuropathic pain, but direct inhibition of AMPARs is associated with side effects. As an alternative, we developed a cell‐permeable, high‐affinity (~2 nM) pep...

Full description

Bibliographic Details
Main Authors: Nikolaj R Christensen, Marta De Luca, Michael B Lever, Mette Richner, Astrid B Hansen, Gith Noes‐Holt, Kathrine L Jensen, Mette Rathje, Dennis Bo Jensen, Simon Erlendsson, Christian RO Bartling, Ina Ammendrup‐Johnsen, Sofie E Pedersen, Michèle Schönauer, Klaus B Nissen, Søren R Midtgaard, Kaare Teilum, Lise Arleth, Andreas T Sørensen, Anders Bach, Kristian Strømgaard, Claire F Meehan, Christian B Vægter, Ulrik Gether, Kenneth L Madsen
Format: Article
Language:English
Published: Springer Nature 2020-04-01
Series:EMBO Molecular Medicine
Subjects:
biopharmaceuticals
calcium permeable AMPARs
maladaptive plasticity
scaffold proteins
synaptic plasticity
Online Access:https://doi.org/10.15252/emmm.201911248
Description
Summary:Abstract Maladaptive plasticity involving increased expression of AMPA‐type glutamate receptors is involved in several pathologies, including neuropathic pain, but direct inhibition of AMPARs is associated with side effects. As an alternative, we developed a cell‐permeable, high‐affinity (~2 nM) peptide inhibitor, Tat‐P4‐(C5)2, of the PDZ domain protein PICK1 to interfere with increased AMPAR expression. The affinity is obtained partly from the Tat peptide and partly from the bivalency of the PDZ motif, engaging PDZ domains from two separate PICK1 dimers to form a tetrameric complex. Bivalent Tat‐P4‐(C5)2 disrupts PICK1 interaction with membrane proteins on supported cell membrane sheets and reduce the interaction of AMPARs with PICK1 and AMPA‐receptor surface expression in vivo. Moreover, Tat‐P4‐(C5)2 administration reduces spinal cord transmission and alleviates mechanical hyperalgesia in the spared nerve injury model of neuropathic pain. Taken together, our data reveal Tat‐P4‐(C5)2 as a novel promising lead for neuropathic pain treatment and expand the therapeutic potential of bivalent inhibitors to non‐tandem protein–protein interaction domains.
ISSN:1757-4676
1757-4684

Similar Items